Neurocrine Biosciences, Inc (NASDAQ:NBIX)’s traded shares stood at 0.88 million during the last session, with the company’s beta value hitting 0.22. At the close of trading, the stock’s price was $120.18, to imply an increase of 0.89% or $1.06 in intraday trading. The NBIX share’s 52-week high remains $157.98, putting it -31.45% down since that peak but still an impressive 29.91% since price per share fell to its 52-week low of $84.23.
Analysts have given a consensus recommendation of Buy for Neurocrine Biosciences, Inc (NBIX), translating to a mean rating of 1.37. Of 14 analyst(s) looking at the stock, 1 analyst(s) give NBIX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 12 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 1.5.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) trade information
After registering a 0.89% upside in the last session, Neurocrine Biosciences, Inc (NBIX) has traded red over the past five days. The 5-day price performance for the stock is -0.69%, and 13.63% over 30 days. With these gigs, the year-to-date price performance is -11.96%.
The extremes give us $150 and $168 for target low and target high price respectively. As such, NBIX has been trading -39.79% off suggested target high and -24.81% from its likely low.
Neurocrine Biosciences, Inc (NBIX) estimates and forecasts
The rating firms project that company’s revenue will grow 14.08% compared to the previous financial year.
Revenue forecast for the current quarter as set by 21 analysts is 653.09M. Meanwhile, for the current quarter, a total of 20 analyst(s) estimate revenue growth to 719.92M.Earnings reports from the last fiscal year show that sales brought in 590.2M and 622.1M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 10.66% before jumping 15.72% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 53.47% for the past 5-year period. While 2025 is set for a 21.64% return in earnings, projections for the next 5 years are at 34.79% annually.
NBIX Dividends
Neurocrine Biosciences, Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 10.06 million shares, or about 9.9766% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.38 billion.
We also have iShares Trust-iShares Core S&P Mid-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Neurocrine Biosciences, Inc (NBIX) shares. Going by data provided on Mar 31, 2025 , iShares Trust-iShares Core S&P Mid-Cap ETF holds roughly 3.26 shares. This is just over 3.29% of the total shares, with a market valuation of $391.38 million. Data from the same date shows that the other fund manager holds a little less at 3.18, or 3.21% of the shares, all valued at about 382.32 million.
